With our partners in the Stratified Medicine Scotland Innovation Centre, we are making significant investments in this field.
What is stratified medicine?
Stratified medicine involves examining the genetic makeup of patients and their differing responses to drugs designed to treat specific diseases.
By building up an understanding of the ‘strata’ of responses and the genetics of the diseases, medical researchers hope to create more personalised and effective forms of treatment for groups of patients most likely to benefit.
Significant past investment in Scotland in electronic health records (EHRs) and translational medicine research, coupled with a vibrant healthcare technology industry, positions Scotland as the location to drive forward the stratified medicine agenda globally.
Postgraduate taught degree
We offer an innovative new MSc programme in Stratified Medicine and Pharmacological Innovation. The course comprises a combination of core and optional modules, and a choice of research project – many of which will be supplied by the core facility or its industry partners
Stratified Medicine Scotland Innovation Centre
The Centre combines cutting-edge genetic research with state-of-the-art health informatics and imaging technologies.
It is a unique collaboration in healthcare between partners from academia, the NHS and the pharmaceutical industry.
The SMS-IC at a glance
The SMS-IC brings together expertise and funding from:
- the Scottish Funding Council
- Health Science Scotland
- NHS Scotland
- the Universities of Glasgow, Aberdeen, Dundee and Edinburgh
- core industry partners, Aridhia and Life Technologies.
Additional support has been received from Glasgow City Council and Scottish Enterprise. Also affiliated are five large global life science companies, six local SMEs and the University of Strathclyde.
Recent analysis suggests that the centre has the potential to generate:
- £10.4m of new clinical trial income in Scotland
- £61m in new revenues accruing to 2017 and beyond
- 334 new industry jobs (direct and indirect)
- more than £68m gross value added impact over the five-year funding horizon, with a target of 20% accruing to SMEs.
The research findings of the SMS-IC could also result in significant healthcare savings. Of the £595bn global spend for pharmaceuticals in 2011, an estimated £393bn was used for therapies that did not produce the desired effect.